UK Markets open in 1 hr 21 mins

TherapeuticsMD, Inc. (TXMD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.67-0.27 (-3.89%)
At close: 04:00PM EDT
7.00 +0.33 (+4.95%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close6.94
Open6.83
Bid0.00 x 1200
Ask0.00 x 3200
Day's range6.59 - 6.99
52-week range1.99 - 41.00
Volume45,777
Avg. volume492,464
Market cap2.834B
Beta (5Y monthly)1.95
PE ratio (TTM)N/A
EPS (TTM)-0.67
Earnings date09 Nov 2022 - 14 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est65.00
  • Business Wire

    TherapeuticsMD Announces $7 Million Private Placement

    BOCA RATON, Fla., October 03, 2022--TherapeuticsMD, Inc. (NASDAQ: TXMD), ("TherapeuticsMD" or the "Company") an innovative, leading women’s healthcare company, announced today that it received a $7 million private investment in the Company’s Series A Preferred Stock from Rubric Capital Management LP ("Rubric"). TherapeuticsMD expects to use the proceeds from the transaction for working capital.

  • Business Wire

    TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers

    BOCA RATON, Fla., September 12, 2022--TherapeuticsMD, Inc. (NASDAQ: TXMD), ("TherapeuticsMD" or the "Company") an innovative, leading women’s healthcare company, announced today the appointment of Dr. Brian Bernick and Mr. Mark Glickman as the Company’s Interim Co-Chief Executive Officers and Co-Principal Executive Officers. Dr. Bernick and Mr. Glickman succeed Mr. Hugh O’Dowd as the Company’s Chief Executive Officer.

  • Motley Fool

    TherapeuticsMD, Inc. (TXMD) Q2 2022 Earnings Call Transcript

    Good morning, everyone, and thank you for joining today to discuss our second quarter financial results and business update. This morning, TherapeuticsMD issued a press release announcing its second quarter 2022 financial results. The press release and accompanying presentation are available on the company's website TherapeuticsMD in the investors and media section.